Drug Development Pharma - January 12, 2015
FDA OKs Novo Weight-Loss Drug
Two months after its own deadline, the U.S. Food and Drug Administration (FDA) issued approval for Novo Nordisk’s first weight-loss therapy. Approved was Novo’s Saxenda for use in managing weight in conjunction with diet and exercise. Saxenda is a higher dose of the diabetes treatment liraglutide. The drug is indicated for patients who qualify as […]
